Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome by Iurlo, Alessandra et al.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2016
Imatinib and polypharmacy in very old patients with chronic 
myeloid leukemia: effects on response rate, toxicity and 
outcome
Alessandra Iurlo1, Alessandro Nobili2, Roberto Latagliata3, Cristina Bucelli1, 
Fausto Castagnetti4, Massimo Breccia3, Elisabetta Abruzzese5, Daniele Cattaneo1, 
Carmen Fava6, Dario Ferrero7, Antonella Gozzini8, Massimiliano Bonifacio9, Mario 
Tiribelli10, Patrizia Pregno11, Fabio Stagno12, Paolo Vigneri12, Mario  Annunziata13, 
Francesco Cavazzini14, Gianni Binotto15, Giovanna Mansueto16, Sabina Russo17, 
Franca Falzetti18, Enrico Montefusco19, Gabriele Gugliotta4, Sergio Storti20, Ada M. 
D’Addosio21, Luigi Scaffidi9, Laura Cortesi2, Michele Cedrone22, Antonella Russo 
Rossi23, Paolo Avanzini24, Endri Mauro25, Antonio  Spadea26, Francesca Celesti27, 
Gianfranco Giglio28, Alessandro Isidori29, Monica Crugnola30, Elisabetta  Calistri31, 
Federica Sorà32, Giovanna Rege-Cambrin6, Simona Sica32, Luigiana Luciano33, Sara 
Galimberti34, Ester M. Orlandi35, Monica Bocchia36, Mauro Tettamanti2, Giuliana 
Alimena3, Giuseppe Saglio6, Gianantonio Rosti4, Pier Mannuccio Mannucci37 and 
Agostino Cortelezzi1
1 Oncohematology Division, IRCCS Ca’ Granda - Maggiore Policlinico Hospital Foundation, University of Milan, Milan, Italy
2 Department of Neuroscience, IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
3 Department of Cellular Biotechnologies and Hematology, University “La Sapienza” of Rome, Rome, Italy
4 Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, “S. Orsola-
Malpighi” University Hospital, University of Bologna, Bologna, Italy
5 Hematology Unit, Sant’Eugenio Hospital, Rome, Italy
6 Division of Hematology and Internal Medicine, University of Turin, “San Luigi Gonzaga” University Hospital, Orbassano, 
Turin, Italy
7 Hematology Unit, University of Turin, Turin, Italy
8 Haematology, AOU Careggi, University of Firenze, Firenze, Italy
9 Department of Medicine, Section of Hematology, University of Verona, Verona, Italy
10 Division of Hematology and BMT, Azienda Ospedaliero - Universitaria di Udine, Udine, Italy
11 Hematology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Turin, Italy
12 Hematology Unit, Ferrarotto Hospital, Catania, Italy
13 Hematology Unit, Cardarelli Hospital, Naples, Italy
14 Hematology Unit, University of Ferrara, Ferrara, Italy
15 Hematology Unit, University of Padova, Padova, Italy
16 Department of Onco-Hematology, IRCCS-CROB, Rionero in Vulture, Italy
17 Hematology Unit, AOU G. Martino, Messina, Italy
18 Division of Hematology and Clinical Immunology, Department of Medicine, University of Perugia, Perugia, Italy
19 Hematology Unit, Sant’Andrea Hospital, Rome, Italy
20 Onco-Hematology Unit, Università Cattolica Giovanni Paolo II, Campobasso, Italy
21 Immunohematology and Trasfusional Medicine Division, S. Pietro Fatebenefratelli Hospital, Rome, Italy
22 Hematology Unit, S. Giovanni Hospital, Rome, Italy
23 Hematology and Transplants Unit, University of Bari, Bari, Italy
24 Hematology, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy
25 Department of Internal Medicine, Pordenone General Hospital, Pordenone, Italy
26 Hematology and Stem Cell Transplantation Unit, Regina Elena Institute, Rome, Italy
Oncotarget2www.impactjournals.com/oncotarget
INTRODUCTION
Chronic myeloid leukemia (CML) has an annual 
incidence of 1.1-1.8 cases per 100,000 adults, accounting 
for 15-20% of newly diagnosed cases of leukemia in adults 
[1]. The median age at diagnosis is 50-60 years, with a 
peak at 70-74 years [2]. Thus, a significant proportion of 
CML patients are old or very old. In the past the primary 
aim of treatment in this subset of patients was to contain 
the leukemic mass, because older patients had no access 
to appropriate therapies like interferon or allogeneic bone 
marrow transplantation [3]. Patients’ prognosis changed 
dramatically with the development of tyrosine kinase 
inhibitors (TKIs). This targeted approach has markedly 
increased the survival of CML patients, which is now 
approaching that of the general population [1, 4, 5].
Even though a relevant proportion of CML 
patients are old or very old, they are generally under-
represented in clinical trials [2]. Moreover, older TKI-
treated patients suffer from comorbidities, whose number 
is usually higher in patients aged 75 years or more [6]. 
Several studies have established that multimorbidity is an 
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ABSTRACT
Background: About 40% of all patients with chronic myeloid leukemia are currently 
old or very old. They are effectively treated with imatinib, even though underrepresented 
in clinical studies. Furthermore, as it happens in the general population, they often 
receive multiple drugs for associated chronic illnesses. Aim of this study was to 
assess whether or not in imatinib-treated patients aged >75 years the exposure to 
polypharmacy (5 drugs or more) had an impact on cytogenetic and molecular response 
rates, event-free and overall survival, as well as on hematological or extra-hematological 
toxicity.
Methods: 296 patients at 35 Italian hematological institutions were evaluated.
Results: Polypharmacy was reported in 107 patients (36.1%), and drugs more 
frequently used were antiplatelets, diuretics, proton pump inhibitors, ACE-inhibitors, 
beta-blockers, calcium channel blockers, angiotensin II receptors blockers, statins, oral 
hypoglycemic drugs and alpha blockers. Complete cytogenetic response was obtained 
in 174 patients (58.8%), 78 (26.4%) within 6 month, 63 (21.3%) between 7 and 12 
months. Major molecular response was obtained in 153 patients (51.7%), 64 (21.6%) 
within the 12 month. One hundred and twenty-eight cases (43.2%) of hematological 
toxicity were recorded, together with 167 cases (56.4%) of extra-hematological toxicity. 
Comparing patients exposed to polypharmacy to those without, no difference was 
observed pertaining to the dosage of imatinib, cytogenetic and molecular responses 
and hematological and extra-hematological toxicity.
Conclusion: Notwithstanding the several interactions reported in the literature 
between imatinib and some of the medications considered herewith, this fact does not 
seem to have a clinical impact on response rate and outcome.
Oncotarget3www.impactjournals.com/oncotarget
Table 1: General characteristics of 296 chronic-phase CML patients, overall and according to the exposure or not to 
polypharmacy.
Variables Overall cohort(n. 296) %
No polypharmacy (A)
(N of drugs 0-4)
(n. 189)
%
On polypharmacy 
(B)
(N of drugs >5)
(n. 107)
% A vs Bp value
Male, n (%) 152 51.4 95 50.3 57 53.3 0.61
Mean age ± SD 79.4 ± 3.7 79.0 ± 3.6 80.1 ± 3.7 0.01
Clinical parameters
Sokal score, n (%)
Low 4 1.4 3 1.6 1 0.9
0.83
Intermediate 187 63.2 116 61.4 71 66.4
High 83 28.0 55 29.1 28 26.2
Not available 22 7.4 15 7.9 7 6.5
Imatinib dosage, n (%)
<400 mg/day 103 34.8 61 32.3 42 39.3
0.22
>400 mg/day 193 65.2 128 67.7 65 60.7
CCI, n (%)
0 105 35.5 79 41.8 26 24.3
0.0041 74 25.0 47 24.9 27 25.2
2+ 117 39.5 63 33.3 54 50.5
Concomitant drugs
Antihypertensives, 
n (%) 214 72.3 117 61.9 97 90.7 <0.0001
Diuretics, n (%) 123 41.6 51 27.0 72 67.3 <0.0001
ACE inhibitors, n (%) 81 27.4 40 21.2 41 38.3 0.0015
Beta-blockers, n (%) 59 19.9 18 9.5 41 38.3 <0.0001
Calcium channel blockers, 
n (%) 57 19.3 25 13.2 32 29.9 0.0005
Angiotensin II receptor 
blockers, n (%) 55 18.6 24 12.7 31 29.0 0.0005
Alpha blockers, n (%) 27 9.1 9 4.8 18 16.8 0.0005
Antiplatelet agents, 
n (%) 144 48.6 70 37.0 74 69.2 <0.0001
Proton pump inhibitors, n 
(%) 122 41.2 52 27.5 70 65.4 <0.0001
Statins, n (%) 43 14.5 15 7.9 28 26.2 <0.0001
Oral hypoglycemic drugs, 
n (%) 40 13.5 18 9.5 22 20.6 0.007
Clinical outcomes
CCyR, n (%) 174 58.8 113 59.8 61 57.0 0.69
CCyR within 6 months, n 
(%) 78 26.4 49 25.9 29 27.1 0.57
CCyR 7 to 12 months, n 
(%) 63 21.3 42 22.2 21 19.6 0.80
MMR, n (%) 153 51.7 93 49.2 60 56.1 0.49
Hematological toxicity, n 
(%) 126 42.6 79 41.8 47 43.9 0.72
Extra-hematological 
toxicity, n (%) 167 56.4 107 56.6 60 56.1 0.92
Abbreviations: SD=standard deviation; CCI=Charlson Comorbidity Index; CCyR=Complete Cytogenetic Response; 
MMR=Major Molecular Response.
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independent predictor of all-cause mortality [7-9]: more 
specifically, a recent study by Saussele et al. [6] on the 
influence of comorbidities on the outcome of 1519 CML 
patients found a strong negative association between 
comorbidities at diagnosis and overall survival (OS), 
even though comorbidities had no impact on treatment 
success. Furthermore, Efficace et al. [10] reported that 
comorbidities have a critical impact also on the health-
related quality of life of these patients, particularly on 
general health, pain, physical functioning and vitality.
Due to multiple concomitant diseases, medication 
intake usually increases in older people, so that 
polypharmacy, a well-known risk factor for drug-drug 
interactions (DDIs) and adverse drug reactions (ADR), 
is highly prevalent. In older people, these risks are also 
increased because ageing is often accompanied by 
physiological changes in the pharmacokinetic (PK) and 
pharmacodynamic processes [11, 12]. In older CML cases 
exposed to polypharmacy, the use of TKIs may be another 
risk factor for DDIs, because these drugs are extensively 
metabolized by cytochrome (CYP) P450.
In addition, some TKIs are substrates or inhibitors of 
the drug transporter P-glycoprotein (PgP) and the organic 
cation transporter 1 (hOCT1). In particular, imatinib is 
metabolized primarily by the CYP 3A4 isoenzyme and is 
a substrate for hOCT1, PgP and breast cancer resistance 
protein (BCRP). The classes of drugs most commonly 
involved in DDIs with TKIs, and specifically with 
imatinib, are anticoagulants, proton pump inhibitors (PPI), 
antiplatelet agents, calcium channel blockers, statins, 
antiarrhythmic drugs, beta-blockers, digoxin, macrolides, 
azoles, rifampicin, dexamethasone and levothyroxine 
[13]. As a result of the effect of potential DDIs between 
concomitantly administered drugs, a standard regimen of 
TKIs may produce different levels of circulating and intra-
cellular drug concentrations. Thus, a patient could on one 
hand have a low response to TKI due to subtherapeutic 
drug exposure or on the other hand develop TKI toxicity 
in case of overexposure. However, data specifically on 
concomitant medications in CML are not reported in the 
literature.
With this background, the aim of this study was 
to assess if in CML patients aged 75 years or more and 
imatinib-treated the exposure to polypharmacy had an 
impact on such main clinical outcomes as cytogenetic and 
molecular response rates, event-free survival (EFS) and 
OS, as well as on hematological or extra-hematological 
toxicity.
RESULTS
Two hundred and ninety-six very old patient with 
chronic-phase CML treated with imatinib were evaluated. 
Table 1 summarizes the characteristics of the whole cohort 
and of patients exposed to polypharmacy (5 or more 
drugs) compared with those not exposed to polypharmacy 
(less than 5 drugs).
In the overall cohort, mean age at diagnosis was 
79.4 (± 3.7 SD) years, 152 (51.4%) were males, 83 (28%) 
were Sokal high risk and 103 (34.8%) were treated with 
reduced dose imatinib (< 400 mg/day). Seventy-one 
patients (24%) received other treatments before imatinib, 
mainly hydroxyurea (62 patients; 20.9%) and/or interferon 
(9 patients; 3%).
Polypharmacy was present in 107 patients (36.1%), 
and the concomitant drugs more frequently used were 
antiplatelet agents taken by 152 patients (51.4%), followed 
by diuretics and PPIs in 125 (42.3%), ACE-inhibitors 
in 83 (28%), beta-blockers in 61 (20.6%), calcium 
channel blockers in 59 (19.9%), angiotensin II receptor 
blockers (ARB) in 57 (19.3%), statins in 44 (14.9%), oral 
hypoglycemic drugs in 38 (12.8%) and alpha blockers in 
31 (10.5%).
Complete cytogenetic response was obtained in 
174 patients (58.8%), 78 (26.4%) within 6 month, 63 
(21.3%) between 7 and 12 months, and the remaining 
patients after 12 months. Major molecular response 
(MMR) was obtained in 153 patients (51.7%), of whom 
64 (21.6%) within the 12th month. However, differently 
from molecular analyses, a cytogenetic evaluation was 
not available in 58 patients (19.6%). One hundred and 
twenty-eight cases (43.2%) of hematological toxicity 
were recorded, together with 167 cases (56.4%) of extra-
hematological toxicity.
Comparing patients exposed to polypharmacy with 
those without polypharmacy, a statistically significant 
difference between the two groups was observed for age 
and comorbidities. No difference was found in the two 
groups pertaining to the dosage of imatinib, cytogenetic 
and molecular responses and hematological and extra-
hematological toxicity (Table 1).
According to the starting dosage of imatinib, 193 
patients (65.2%) were treated with 400 mg/day or more. 
The comparison of characteristics of patients treated with 
less than 400 mg/day and those treated with 400 mg/day or 
more showed a statistically significant difference only for 
age, concomitant use of antiplatelet and oral hypoglycemic 
agents, as well as for cytogenetic response by 12 months 
(Table 1S).
At multivariable logistic regression analysis 
(Table 2), polypharmacy was not associated at any time 
point with cytogenetic response, molecular response 
and hematological and extra-hematological toxicity. 
Furthermore, the exposure to polypharmacy failed to 
affect patient outcomes (EFS p = 0.79; OS p = 0.74) 
(Figure 1a and 1b), even though we confirmed the impact 
that comorbidities had on EFS (p = 0.001) or OS (p < 
0.001) (Figure 1S.a and 1S.b).
Finally, the exposure to multiple concomitant drugs 
(in particular, classes of antihypertensives, antiplatelet 
agents, PPIs, statins or oral hypoglycemic drugs) had no 
statistically significant effect on OS, EFS, cytogenetic 
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Table 2: Response rate and toxicity of 296 chronic-phase CML patients aged 75 years or older according to the exposure 
or not to polypharmacy.
Clinical outcomes Patients (n. 296)
No polypharmacy
(N of drugs 0-4)
(n. 192)
Polypharmacy
(N of drugs >5)
(n. 104)
Univariate
OR (95% CI)
Multivariable*
OR (95% CI)
CCyR within 6 months, n (%) 50 (26) 28 (26.9) 0.81 (0.46-1.43) 0.96 (0.86-1.09)
CCyR 7 to 12 months, n (%) 43 (22.4) 20 (19.2) 0.91 (0.53-1.56) 0.96 (0.86-1.08)
MMR, n (%) 93 (48.4) 60 (57.7) 0.84 (0.51-1.38) 1.00 (0.90-1.11)
Hematological toxicity, n (%) 80 (41.7) 46 (44.2) 0.93 (0.57-1.52) 1.03 (0.93-1.14)
Extra-hematological toxicity, n (%) 108 (56.3) 59 (56.7) 1.33 (0.82-2.17) 1.05 (0.95-1.17)
Abbreviations: OR=Odds Ratio; CCyR=complete cytogenetic response; MMR=major molecular response.
* Adjusted for age and sex.
Figure 1: a. Event-free survival according to the exposure or not to polypharmacy. b. Overall survival according to the exposure or not 
to polypharmacy.
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response at any time-point, molecular response and 
hematological and extra-hematological toxicity (Table 2S).
DISCUSSION
Imatinib is a very effective treatment also for older 
CML patients in chronic phase, allowing high response 
rates and survival, comparable to those observed in the 
younger [14]. However, several older patients actually 
receive a starting dose of imatinib < 400 mg/day, i.e. lower 
than the standard dose, owing to worse performance status 
compared to younger ones [15].
While the prognostic impact of comorbidities on 
CML has been previously studied, establishing their strong 
negative influence [6, 16], there are no data concerning 
the role that multiple drugs may have regarding response 
rate or outcome during imatinib therapy in very old CML 
patients. Indeed, there is a list of observed or potential 
DDIs between first and second generation TKIs (imatinib, 
dasatinib and nilotinib) and commonly used drugs which 
are concomitantly prescribed [13, 17], but this list is 
mainly the result of meta-analyses regarding in vitro 
studies rather than of in vivo studies. To address this issue, 
we retrospectively evaluated a large cohort of 296 patients 
from 35 Italian hematological centers aged 75 years or 
more at the time of imatinib start. Our data show that in 
36.1% of these cases 5 or more concomitant drugs were 
regularly co-prescribed, and that diuretics, beta-blockers 
and statins were the most frequently used [18].
The achievement of CCyR at 6 and 12 months and 
of MMR were not influenced by the number and type of 
concomitant drugs. Similarly, the incidence and type of 
reported ADRs were not apparently influenced by the type 
and number of co-treatments. This is perhaps due to the 
variety of conditions in which combination therapies were 
analyzed, adding a level of treatment complexity owing to 
overlapping PK interactions (i.e. absorption, distribution, 
metabolism) [19]. Most importantly, at variance with 
comorbidities that did significantly influence patient 
outcome also in the present cohort, concomitant drugs and 
single classes of drugs failed to affect EFS or OS in old 
CML patients.
This is the first study which specifically considers 
the prognostic significance of TKIs and concomitant drug 
exposure in a large population of very old CML patients 
outside the context of a prospective clinical trial. However, 
we are aware that our study has some limitations: namely, 
its retrospective nature and the lack of information 
regarding the severity of the comorbidities, the latter due 
to the fact that they were evaluated by means of Charlson 
Comorbidity Index (CCI).
Notwithstanding the several PK interactions 
reported in the literature between imatinib and some of 
the medications considered herewith [13, 17], this does 
not seem to have a clinical impact on the response rate 
and outcome also in a real-life setting. Thus, we believe 
that an older age and a worse performance status are 
still fully compatible with TKIs use (and effectiveness), 
at variance with more aggressive cytotoxic treatments 
actually used in other hematological malignancies. Our 
findings may represent useful information for clinicians, 
allowing them to manage their very old CML patients in 
chronic phase in the best possible way. More specifically, 
it should be further considered that efficacy and safety 
of different co-prescribed drugs can be up- or down-
regulated by imatinib: for example, imatinib enhances the 
pharmacologic effects and possibly toxicity of cyclosporin, 
simvastatin, metoprolol, calcium channel blockers such as 
verapamil and diltiazem, amiodarone, and quinidine [13]. 
Therefore, in patients taking imatinib, these drugs should 
be either tapered or replaced by safer alternatives.
In conclusion, the prognosis of very old CML 
cases depended more on their comorbidities than on the 
number of drugs taken. Furthermore, a larger number of 
CML patients will have a life expectancy similar to that of 
general population, and this mainly due to TKIs treatment.
With this study we did underline the safety and 
efficacy of imatinib also in this subset of patients. It 
could be interesting to evaluate also the impact of second 
generation TKIs (dasatinib, nilotinib and bosutinib).
MATERIALS AND METHODS
Patients
In the frame of this observational study 35 Italian 
hematological centers were asked to retrospectively collect 
data on all CML patients on chronic phase admitted from 
January 2002 to October 2015, provided they were aged 
75 years or more at the time of imatinib start.
Methods
All the following data were collected at baseline 
before imatinib initiation: sociodemographic and 
hematological variables, type and number of concomitant 
diseases and drugs and initial dose of imatinib. Any 
diagnosed clinical condition requiring a specific and 
chronic treatment was considered a concomitant disease 
and assessed as defined in the CCI [20]. Hematological 
and extra-hematological toxicities were graded according 
to the WHO scale, but for the purpose of this study only 
severe toxicities were considered in the analysis.
We defined polypharmacy according to the REPOSI 
registry as exposure of a CML patient to five or more 
different medications in addition to imatinib [21]. In 
particular, we analyzed the effects of drugs that may 
have a potential risk of interaction with imatinib, such as 
antihypertensives, ACE-inhibitors, beta-blockers, calcium 
channel blockers, ARB, antiplatelet agents, PPI, statins 
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and oral hypoglycemic drugs [13].
Monitoring and responses followed the current 
European LeukemiaNet recommendations [22-24].
Overall survival was calculated from the date of 
imatinib start until death due to any cause. Event-free 
survival was calculated from the date of imatinib start 
to any of the following events: primary hematological 
resistance to imatinib, definitive imatinib discontinuation 
due to toxicity or any other cause, secondary hematological 
or cytogenetic resistance to imatinib or death due to any 
cause.
Statistical analysis
Clinical and sociodemographic characteristics 
of the sample were described using absolute numbers 
and percentages, except that for age mean and standard 
deviation (SD) were used. Comparison between subgroups 
with and without polypharmacy, or with dosage of 
imatinib lower/higher than 400 mg/day were performed 
by means of chi square test for all variables except for 
age, where a t-test was used. The univariable association 
between polypharmacy and CCyR (0 to 6 months, 7 to 
12 months, more than 12 months) was studied using an 
ordinal logistic regression model and reporting odds 
ratios (ORs) and 95% confidence intervals (CIs). The 
associations between polypharmacy and molecular 
response (MR), hematological or extra-hematological 
toxicity were studied using nominal logistic regression 
models and reporting ORs and 95% CIs. Multivariable 
ordinal/nominal logistic regressions for all models were 
performed correcting for age and sex. Kaplan-Meier 
curves were plotted to analyze differences in survival from 
the beginning of imatinib therapy to the occurrence of OS 
or EFS by presence of polypharmacy, testing differences 
by means of log-rank tests. Cox proportional hazards 
models were used to obtain the hazard ratios (HRs) of 
OS or EFS for polypharmacy in a multivariable models 
(adjusting for age and sex). Single drug class associations 
with CCyR, MR, toxicity, OS or EFS were analyzed as 
reported above for polypharmacy. Categorized age was 
used in multivariable models to correct for imbalances. 
Statistical analyses were performed using JMP Pro 12.1 
(SAS Institute Inc.).
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